Progenics Pharmaceuticals, Inc. (PGNX) Position Raised by Legal & General Group Plc

Legal & General Group Plc boosted its position in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 11.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 145,420 shares of the biotechnology company’s stock after buying an additional 15,320 shares during the quarter. Legal & General Group Plc owned approximately 0.19% of Progenics Pharmaceuticals worth $1,172,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Progenics Pharmaceuticals by 14.0% in the 2nd quarter. BlackRock Inc. now owns 11,391,237 shares of the biotechnology company’s stock worth $91,584,000 after purchasing an additional 1,401,564 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in Progenics Pharmaceuticals by 1.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,389,840 shares of the biotechnology company’s stock worth $11,174,000 after purchasing an additional 15,378 shares in the last quarter. Royce & Associates LP raised its holdings in Progenics Pharmaceuticals by 1.3% in the 2nd quarter. Royce & Associates LP now owns 1,177,256 shares of the biotechnology company’s stock worth $9,465,000 after purchasing an additional 15,000 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Progenics Pharmaceuticals by 2.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,062,981 shares of the biotechnology company’s stock worth $8,546,000 after purchasing an additional 24,073 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its holdings in Progenics Pharmaceuticals by 529.5% in the 1st quarter. Summit Trail Advisors LLC now owns 408,376 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 343,505 shares in the last quarter. Institutional investors own 88.74% of the company’s stock.

Shares of Progenics Pharmaceuticals stock opened at $5.95 on Monday. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.34 and a quick ratio of 6.34. The stock has a market capitalization of $472.50 million, a P/E ratio of -6.61 and a beta of 2.50. Progenics Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.42.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.02). The business had revenue of $3.88 million during the quarter, compared to the consensus estimate of $3.30 million. Progenics Pharmaceuticals had a negative return on equity of 94.45% and a negative net margin of 341.41%. Equities research analysts expect that Progenics Pharmaceuticals, Inc. will post -0.67 earnings per share for the current fiscal year.

PGNX has been the subject of several research reports. BidaskClub upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 20th. Needham & Company LLC upped their price objective on shares of Progenics Pharmaceuticals from $14.00 to $16.00 and gave the stock a “strong-buy” rating in a report on Tuesday, July 31st. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $13.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. Finally, ValuEngine upgraded shares of Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $11.69.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Further Reading: Do Tariffs Work?

Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply